Protara Therapeutics (NASDAQ:TARA - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09, Zacks reports.
Protara Therapeutics Stock Performance
Shares of NASDAQ TARA traded up $0.10 during midday trading on Friday, reaching $4.02. 188,072 shares of the company traded hands, compared to its average volume of 317,690. The firm has a market cap of $82.93 million, a PE ratio of -1.43 and a beta of 1.69. The stock's 50-day simple moving average is $4.56 and its 200-day simple moving average is $3.42. Protara Therapeutics has a 12 month low of $1.60 and a 12 month high of $10.48.
Wall Street Analysts Forecast Growth
TARA has been the topic of several analyst reports. Guggenheim reiterated a "buy" rating and set a $20.00 price target on shares of Protara Therapeutics in a report on Friday, December 6th. HC Wainwright reaffirmed a "buy" rating and issued a $23.00 target price on shares of Protara Therapeutics in a research report on Thursday.
Get Our Latest Research Report on TARA
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Featured Stories
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
